Toggle navigation
Home
Search
Services
Blog
Contact
About
Recombinant Human C1 Inhibitor for Treatment of Heredit*
Nuijens, Jan H.
Pharming Technologies, B.V., Leiden, Netherlands
Search grants from Jan Nuijens
Search grants from Pharming Technologies, B.V.
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Overcoming Resistance to Engraftment in Non-myeloablated Recipients
Biosynthesis of Microbial Products
Growth Factor Effects on Proximal Tubule Transport
Vascular Adaptation in Pathophysiology
Massachusetts 1987 Safe Roads Act/Traffic Safety Program
Recently added grants:
Heterogeneous Loss of GDF11 Tumor Suppression in Triple-negative Breast Cancer
FGFR4 intracellular domain promotes tumor progression in cholangiocarcinoma
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
Specificity and function of memory-phenotype CD8+ T cells in the tumor environment
Enabling effective anti-tumor immunity from targeted antibodies through dual innate and adaptive immune checkpoint blockade in non-immunogenic cancers
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Research Project (R01)
Project #
3R01FD003086-01S1
Application #
7675911
Study Section
Special Emphasis Panel (ZFD1-OPD-L (C1))
Program Officer
Ganti, Usha
Project Start
2006-09-20
Project End
2009-08-31
Budget Start
2006-09-20
Budget End
2009-08-31
Support Year
1
Fiscal Year
2008
Total Cost
Indirect Cost
Institution
Name
Pharming Technologies, B.V.
Department
Type
DUNS #
City
Leiden
State
Country
Netherlands
Zip Code
Related projects
NIH 2008
R01 FD
Recombinant Human C1 Inhibitor for Treatment of Heredit*
Nuijens, Jan H. / Pharming Technologies, B.V.
NIH 2006
R01 FD
Recombinant Human C1 Inhibitor for Treatment of Heredit*
Nuijens, Jan H. / Pharming Technologies, B.V.
Comments
Be the first to comment on Jan Nuijens's grant